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ABSTRACT
Objectives: Molecular profiling of tumours has become the mainstay of diagnostics for metastasised solid
malignancies and guides personalised treatment, especially in nonsmall cell lung cancer (NSCLC). In
current practice, it is often challenging to obtain sufficient tumour material for reliable molecular analysis.
Cell-free DNA (cfDNA) in blood or other bio-sources could present an alternative approach to obtain
genetic information from the tumour. In a retrospective cohort we analysed the added value of cfDNA
analysis in pleural effusions for molecular profiling.
Methods: We retrospectively analysed both the supernatant and the cell pellet of 44 pleural effusions
sampled from 39 stage IV patients with KRAS (n=23) or EGFR (n=16) mutated tumours to detect the
original driver mutation as well as for EGFR T790M resistance mutations. Patients were diagnosed with
either NSCLC (n=32), colon carcinoma (n=4), appendiceal carcinoma (n=2) or adenocarcinoma of
unknown primary (n=1). Samples collected in the context of routine clinical care were stored at the
Netherlands Cancer Institute biobank. We used droplet digital PCR for analysis.
Results: The driver mutation could be detected in 36 of the 44 pleural effusions by analysis of both the
supernatant (35 out of 44 positive) and the cell pellet (31 out of 44 positive). In seven out of 20 pleural
effusions from patients with EGFR mutation-positive tumours, a T790M mutation was detected. All seven
supernatants and cell pellets were positive.
Conclusions: cfDNA in pleural effusion can be used to detect driver mutations as well as resistance
mechanisms like EGFR T790M in pleural effusion with high accuracy and is therefore a valuable
bio-source.
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In current practice, molecular profiling of tumours has become essential to offer targeted therapy for
several types of metastasised malignancies. Especially in nonsmall cell lung cancer (NSCLC), targeted
therapy has been shown to be highly effective, and multiple tyrosine kinase inhibitors (TKIs) for activating
mutations or rearrangements in genes like EGFR (epidermal growth factor receptor), BRAF (B-Raf
proto-oncogene serine/threonine kinase), ALK (anaplastic lymphoma kinase) and ROS1 (Ros oncogene 1
receptor tyrosine kinase) have become available [1]. Also, early detection of resistance mutations like
EGFR T790M is important as they can guide the next line of therapy [2].
Unfortunately, obtaining tumour tissue for molecular analysis can be challenging. The site of the tumour
can be difficult to reach and it often requires invasive procedures to obtain adequate amounts of vital
tumour. In this respect, pleural effusion could be an attractive alternative bio-source for molecular analysis,
especially as ∼30% of NSCLC patients develop pleural effusion [3]. Usually, DNA is isolated from a cell
block or a Giemsa slide, but analysis of cell-free DNA (cfDNA) in the supernatant has shown promising
results [4–9]. Moreover, since the amount of tumour cells or the tumour cell percentage is often
insufficient for analysis, this cell-free compartment is highly interesting.
Here, we explore the diagnostic yield of cfDNA analysis in pleural effusion samples from patients with
NSCLC and other cancer types for EGFR and KRAS (KRAS proto-oncogene GTPase) driver mutation
detection, as well as for EGFR resistance mutations. Analyses of cfDNA from the supernatant were
compared head to head with analyses of the cell pellets (figure 1).
Methods
Supernatant and corresponding cell pellets from 39 stage IV patients, presented at the Netherlands Cancer
Institute (Amsterdam, The Netherlands) between 2009 and 2016, with EGFR (n=16) or KRAS (n=23)
mutation-positive tumours were obtained from the Netherlands Cancer Institute biobank. In total, 44
paired (supernatant and cell pellet) samples were available from 39 patients diagnosed with NSCLC
(n=32), colon carcinoma (n=4), appendiceal carcinoma (n=2) and adenocarcinoma of unknown primary
(n=1) (table 1). The reason for pleurocentesis was either diagnostic (n=16) or therapeutic (n=28). These
samples were leftover material that had been stored as routine laboratory assessment after diagnostics.
This study was approved by the Institutional Research Board of the Netherlands Cancer Institute
(CFMPB497).
All driver gene and EGFR T790M mutations were detected in tumour tissue or cytology samples with
clinically validated assays using high-resolution melting, fragment analysis, Sanger sequence analysis,
FIGURE 1 A schematic overview of
the collection of pleural effusion.
After pleurocentesis the fluid was
centrifuged in order to separate the
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MassARRAY technology or next-generation sequencing (NGS) (data not shown). These analyses were
done in multiple hospitals in the Netherlands.
The supernatant was separated from the cell pellet after centrifugation (1700×g for 10 min). The pellet was
resuspended in 0.5 mL of 0.9% NaCl. Both samples were stored at −30°C. In total, 400 μL from the cell
pellet was isolated using the QIAsymphony DSP DNA Midi Kit (Qiagen, Hilden, Germany). At least 10%
from the sample was analysed, from a median eluted volume of 200 μL. cfDNA was isolated from a
median (range) of 1 (0.75–4) mL pleural effusion using the QIAsymphony Circulating DNA kit (Qiagen).
At least 20% of the sample was analysed, from a median eluted volume of 90 μL. The Bio-Rad (Hercules,
CA, USA) QX200 droplet digital PCR (ddPCR) was used for mutation detection using Bio-Rad PrimePCR
ddPCR mutation assays for KRAS (KRAS Screening Multiplex 186-3506), EGFR T790M (dHsaCP2000019
and dHsaCP2000020), EGFR exon 19 deletion screening assay [10], EGFR L858R (dHsaCP2000021 and
dHsaCP2000022) and EGFR G719X (validated laboratory-developed method using IDT (Coralville, IA,
USA) EGFR wild-type for G719 (HEX), EGFR G719S and EGFR G719A (both FAM)). The limit of blank
and the limit of detection were determined for each individual assay using a Clinical and Laboratory
Standards Institute (CLSI) EP17 protocol [11]. Results were analysed using Quantasoft version 1.6.6
(www.quantasoft.com). Supernatant results were normalised to the amount of cfDNA in 1 mL of fluid.
Results
The majority of the 44 paired samples were either both positive (30 out of 44) or both negative (eight out
of 44) for the original driver mutation. In five cases the driver mutation was only detected in the
supernatant and in one case only in the cell pellet (table 2). Thus, in 36 of the 44 paired samples a driver
mutation was detected using both the supernatant and the cell pellet. Testing only the supernatant would
detect 35 of the 36 drivers (97%) and analysis of only the cell pellet would detect 31 of the 36 drivers
(86%). These results indicated that the supernatant was an excellent bio-source for ddPCR driver
detection. Optimal sensitivity was reached when both the cell pellet and supernatant were analysed.
In five paired samples the driver mutation was only detected in the supernatant. Reviewing the cytology
reports for these cases showed that in two of these samples no tumour cells were seen, in two cases no
cytologically analysis was performed and in one case the tumour cell percentage was only 1%. In four of
these cell pellets no mutant copies were found and in one the amount was below the limit of detection. In
one sample only the cell pellet was positive for the primary driver mutation. This cell pellet had a very low
estimated tumour cell percentage and a borderline result of only 1 mutant copy·μL−1 in the cell pellet
(supplementary table S1). No mutant copies were detected in the supernatant by ddPCR. The cfDNA was
isolated from 0.75 mL of supernatant and showed a very low concentration of 0.005 ng·μL−1 measured by
Qubit (Invitrogen, Carlsbad, CA, USA). Therefore, the mutation could easily be missed in our analysis.
To evaluate whether pleural effusion could be used as a bio-source for resistance analysis after progression
on EGFR TKIs we analysed 20 paired pleural effusions sampled from the 16 patients with EGFR-positive
tumours for the presence of EGFR T790M. EGFR T790M was detected in seven out of the 20 paired
samples. All seven supernatants and cell pellets were positive (table 3). Four out of the seven EGFR T790M
mutation-positive pleural effusion samples had very low estimated tumour cell percentages and in one case
no tumour cells were seen by the pathologist (supplementary table S1). Five of the seven pleural effusions
were sampled from patients progressing on first-generation EGFR TKIs (erlotinib, gefitinib). Furthermore,













Patients/samples 39 44 15 4 1 24
Tumour type
Nonsmall cell lung cancer 32 35 15 4 1 17
Colon carcinoma 4 4 4




Data are presented as n.
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two cases with a positive supernatant, but with a cell pellet showing a borderline result of 1 copy·μL−1,
identified two patients with a durable response to osimertinib. The cytology reports of these pleural
effusion samples showed that in one sample no tumour cells were seen and in one sample the tumour cell
percentage was very low (supplementary table S1). These results indicated that the supernatant is a good
bio-source to detect EGFR T790M. In four patients EGFR T790M had already been detected in tumour
tissue samples by clinically validated diagnostic assays. EGFR T790M was confirmed in all four matched
supernatants and cell pellets. Two out of the seven samples were initially taken specifically for molecular
resistance analysis by NGS/TSACP version 1.0 (MiSeq; Illumina, San Diego, CA, USA) using the cell
pellet: in one of these samples NGS could be successfully performed but no T790M mutation was found,
while for the other sample in the end no NGS was done due to a low estimated tumour cell percentage.
Both samples had tumour cell percentages ⩽5% (supplementary table S1).
Discussion
This study investigated whether cfDNA from the supernatant of pleural effusions could be used for
detecting driver mutations and EGFR resistance mutations. Our results clearly show that the cell-free
fraction of pleural effusions is an excellent source for cfDNA and that it can be used to detect driver as
well as resistance mutations effectively with ddPCR. We showed a high concordance rate between the
supernatant and the cell pellet, which is in line with a previous study [6], but a slightly lower rate has been
reported elsewhere [7]. Furthermore, our results suggest that by using cfDNA in pleural effusion as a
bio-source, the molecular testing has gained in sensitivity, and that optimal sensitivity can be reached by
analysing both the supernatant and the cell pellet. In addition to analysis of cfDNA in pleural effusion
from NSCLC patients, we could also detect KRAS mutations in the supernatant samples from patients
with colon carcinoma, appendiceal carcinoma and adenocarcinoma of unknown primary, which has not
been reported before.
In five pleural effusion samples driver mutations were detected only in the supernatant even though no or
very few tumour cells were seen in the cytopathological results. In our study, mutations were only called
when the amount of copies found by ddPCR was above the limit of detection, determined according to
the CLSI EP17 protocol [11]. The limit of detection was set with a confidence level of 99% to prevent
false-positive results. Tumour DNA in the five corresponding cell pellets was not present or too low to
detect the driver mutation. Importantly, since the detection of a driver mutation in the supernatant
provides no proof of actual presence of tumour cells it can at present not be used for staging purposes.
The origin of cfDNA in the supernatant has not been well studied, although several theories have been
TABLE 2 Detection of original driver mutations by droplet digital PCR in paired samples
(supernatant and cell pellet available) of pleural effusions
Supernatant Cell pellet
Driver positive Driver negative Total
Driver positive 30 5 35
Driver negative 1 8 9
Total 31 13 44
Data are presented as n.
TABLE 3 Detection of EGFR T790M by droplet digital PCR in paired samples (supernatant and
cell pellet available) of pleural effusions
Supernatant Cell pellet
T790M positive T790M negative Total
T790M positive 7 0 7
T790M negative 0 13 13
Total 7 13 20
Data are presented as n.
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described [5, 8, 9]. Most likely this cfDNA is released from necrotic cells in the pleural cavity, but may
also have been leaked from the circulation as a transudate. Alternatively, the cfDNA could have been
derived from tumour cells damaged in the pre-analytical phase, e.g. by centrifugation [5], or from
exosomes secreted by the tumour [8, 9]. Therefore, a high detection rate in the supernatant is expected
and also observed in our study. In one pleural effusion sample only the cell pellet was positive for the
driver mutation. Most likely too little tumour DNA was present in the supernatant.
Resistance mutations are subclonal events in the tumour that often occur during TKI treatment. The EGFR
T790M mutation, for example, is common in tumours of patients progressing on first-generation EGFR
TKIs (erlotinib, gefitinib) [2]. Osimertinib is frequently given as alternative treatment after this mutation is
detected in a biopsy of a progressive lesion [2]. As obtaining tumour tissue is challenging and EGFR
T790M is a subclonal event, sensitive techniques are needed for molecular testing. Plasma genotyping is an
alternative approach, but the sensitivity of detecting EGFR T790M in plasma is only 70% [12]. Therefore,
other bio-sources for molecular testing could be useful. In our study, seven paired samples were positive
for EGFR T790M, of which all were concordant between the supernatant and the cell pellet. Based on
these results, both the supernatant and the cell pellet performed equally well as bio-sources for detecting
EGFR T790M. The pleural effusion samples from four of the five patients progressing on first-generation
EGFR TKIs showed a higher amount of T790M copies in both the supernatant and cell pellet compared
with the two patients showing a durable response to osimertinib. In prospective studies it will be
interesting to see if the amount of EGFR T790M copies, measured by ddPCR in the supernatant and cell
pellet of pleural effusions, correlates to outcome in patients with EGFR-positive tumours treated with
osimertinib.
This study is limited by the small sample size. The supernatant performed better as a bio-source than the
cell pellet for detecting EGFR or KRAS primary driver mutations, but not for detecting EGFR T790M.
Studies with a larger sample size are needed to confirm our results. Besides this, we could only compare a
subset of the paired samples with results obtained in molecular diagnostics with NGS/TSACP version 1.0
using the cell pellet. A direct comparison with a larger set of paired samples could confirm the additive
value of using cfDNA in the supernatant as a bio-source for molecular profiling in a clinical setting.
In conclusion, we showed that analysis of cfDNA in pleural effusion can robustly detect EGFR and KRAS
driver mutations and EGFR resistance mutations. Therefore, cfDNA is a valuable bio-source for molecular
testing, even when tumour cell purity is low.
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